Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MabVax Therapeutics has recruited first patient in a randomised, multicenter, double-blind Phase II trial evaluating the safety and efficacy of its vaccine sarcoma.
Subscribe to our email newsletter
The vaccine has been developed to prevent or delay the recurrence sarcoma at Memorial Sloan-Kettering Cancer Center (MSKCC) where preclinical and early clinical development completed in 2009.
MabVax is expected to enroll 126 metastatic sarcoma patients of 16 years or above in its Phase II trail approximately in 15 months.
MabVax has recruited 12 academic medical centers across the country as investigative sites to conduct the Phase II clinical trial.
MabVax said that the vaccine is a trivalent ganglioside vaccine administered with an immunological adjuvant in a series of 10 subcutaneous injections given over an 84-week period.
Moreover, the vaccine is intended to instruct the patient’s immune system to make antibodies against the three ganglioside antigens present on the surface of sarcoma cells.
Earlier, in 2008, MabVax has exclusively licensed the sarcoma vaccine, along with additional vaccines targeting other neuroectodermal and epithelial cancers, from the Sloan-Kettering Institute for Cancer Research.